Article Details
Retrieved on: 2022-09-26 09:02:13
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
As a result, cell and gene therapy (CGT) manufacturers have long worked from scratch, which has led to scale-up challenges: With supply and labor ...
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here